Persistence of CMV-specific anti-HIV CAR T cells after adoptive immunotherapy.
Chengxiang Wu, Nathan M Johnson, Shan Yu, Agnes S Lo, Gautam K Sahu, Preston A Marx, Dorothee von Laer, Gail Skowron, Romas Geleziunas, George M Shaw and 3 more
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Chengxiang WuTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.ORCID 0000-0002-6184-187X
Nathan M JohnsonTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.
Shan YuTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.ORCID 0009-0001-7358-7864
Agnes S LoTufts Medical School, Boston, Massachusetts, USA.
Gautam K SahuRoger Williams Medical Center, Providence, Rhode Island, USA.
Preston A MarxTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.
Dorothee von LaerMedizinische Universität Innsbruck, Innsbruck, Austria.
Gail SkowronRoger Williams Medical Center, Providence, Rhode Island, USA.
Romas GeleziunasGilead Sciences, Foster City, California, USA.
George M ShawDivision of Hematology/Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-2338-4532
Amitinder KaurTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.
Richard P JunghansTufts Medical School, Boston, Massachusetts, USA.
Stephen E BraunTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.ORCID 0000-0002-4521-2678
Funding
Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Advanced generation infection-proof anti-HIV CAR-T with YY1 RNAi to block T cell exhaustion in NHP modelR44AI152709 · NIAID · IT BIO, LLC · PI JUNGHANS, RICHARD P · 2020 to 2024
$3.3M
PURPOSE OF THE NGVB CONTRACT IS TO CONTINUE SUPPORTING GENE THERAPY RESEARCH.75N92019D00018 · OD · INDIANA UNIVERSITY INDIANAPOLIS · 2019 to 2023
$1.7M
Modified CMV-specific T cells to Target HIVR33AI110158 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI BRAUN, STEPHEN EDWARD · 2016 to 2018
$1.5M
High Throughput Multicolor Flow Cytometer Cell AnalyzerS10OD026800 · OD · TULANE UNIVERSITY OF LOUISIANA · PI KAUR, AMITINDER · 2019 to 2019
$594k
Modified CMV-specific T cells to Target HIVR21AI110158 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI BRAUN, STEPHEN EDWARD · 2014 to 2016
$469k
Towards a new clinical trial Advanced infection proof anti HIV gene modified T ceR56AI102847 · NIAID · TUFTS MEDICAL CENTER · PI JUNGHANS, RICHARD P. · 2013 to 2013
$400k
Modifying CMV-specificT cells with a novel bicistronic CD4-CAR/maC46 vector to target HIVF30AI150452 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI JOHNSON, NATHAN MICHEL · 2019 to 2021
$152k
National Institute of Allergy and Infectious Diseases AI102847National Institute of Allergy and Infectious Diseases AI110158National Institute of Allergy and Infectious Diseases AI152709National Institute of Allergy and Infectious Diseases F30AI150452NCRR NIH HHS P51 OD011104NHLBI NIH HHS 75N92019D00018NIAID NIH HHS F30 AI150452NIAID NIH HHS R21 AI110158NIAID NIH HHS R33 AI110158NIAID NIH HHS R44 AI152709NIAID NIH HHS R56 AI102847NIH HHS P51 OD011104NIH HHS S10 OD026800Tulane University School of Medicine Pilot
6 · The paper itself
Abstract
The success of chimeric antigen receptor (CAR)-T cell (Tc) immunotherapy in refractory B-cell acute lymphoblastic leukemia (B-ALL) suggests adaptation of this strategy toward HIV. Because cytomegalovirus (CMV) vaccine vectors generated Tc responses that controlled viral replication, these studies aim to genetically modify CMV-specific Tc with HIV-CAR2 vectors and link HIV immunotherapy to persistent CMV antigen stimulation. To mimic a clinical scenario, rhesus macaques were challenged with the CCR5-tropic simian/human immunodeficiency virus (SHIV-D) prior to antiretroviral therapy (ART). Autologous CMV-specific Tc were transduced with the control CEA-CAR2 or CD4-CAR2/maC46 vectors and reinfused. After stopping ART, the plasma viral load (PVL) in the control rebounded and was sustained above 1.7 × 10
Indexed as
CytomegalovirusHIV InfectionsImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesAnimalsCD4-Positive T-LymphocytesHIV-1HumansMacaca mulattaSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusViral LoadVirus ReplicationReceptors, Chimeric Antigenadoptive immunotherapyCD4-CAR T cellsCMV-specific immune responsespersistence and biodistributionrhesus SHIV-challenge model
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Persistence of CMV-specific anti-HIV CAR T cells after adoptive immunotherapy. · full record | OpenQuestion